B Gustafson1, B Eliasson, U Smith. 1. The Lundberg Laboratory for Diabetes Research, Center of Excellence for Metabolic and Cardiovascular Research, Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Blå Stråket 3, 413 45 Gothenburg, Sweden.
Abstract
AIMS/HYPOTHESIS: Dickkopf-1 (DKK1) is a secreted inhibitor of canonical wingless-type MMTV integration site family (WNT) signalling; the key pathway for cell fate and development. Inhibition of WNT signalling by DKK1 in precursor cells promotes adipogenesis and inhibits osteogenesis. Previous studies have shown that treatment of type 2 diabetic patients with thiazolidinediones (TZDs) reduces bone density and increases risk of bone fractures, while body fat is increased. METHODS: We examined the effect of TZDs on secretion and DKK1 levels in pre-adipocytes and mature adipose cells and also measured circulating DKK1 levels in 11 patients with type 2 diabetes before and after treatment with the TZD rosiglitazone for 90 days. RESULTS: TZDs added in vitro rapidly increased DKK1 protein levels and secretion in both fully differentiated adipose cells and pre-adipocytes undergoing differentiation. In parallel, beta-catenin levels, a marker of canonical WNT signalling, were reduced. Serum levels of DKK1 were also increased in several of the patients with type 2 diabetes after treatment with rosiglitazone for 90 days. CONCLUSIONS/ INTERPRETATION: These results provide a novel mechanism whereby peroxisome proliferator-activated receptor-gamma activation can terminate WNT signalling and promote adipogenesis. Furthermore, they provide an explanation for why TZD treatment can lead to reduced bone formation and increased risk of fractures, since inhibited WNT signalling in progenitor cells promotes adipogenesis while osteogenesis is reduced.
AIMS/HYPOTHESIS: Dickkopf-1 (DKK1) is a secreted inhibitor of canonical wingless-type MMTV integration site family (WNT) signalling; the key pathway for cell fate and development. Inhibition of WNT signalling by DKK1 in precursor cells promotes adipogenesis and inhibits osteogenesis. Previous studies have shown that treatment of type 2 diabeticpatients with thiazolidinediones (TZDs) reduces bone density and increases risk of bone fractures, while body fat is increased. METHODS: We examined the effect of TZDs on secretion and DKK1 levels in pre-adipocytes and mature adipose cells and also measured circulating DKK1 levels in 11 patients with type 2 diabetes before and after treatment with the TZDrosiglitazone for 90 days. RESULTS:TZDs added in vitro rapidly increased DKK1 protein levels and secretion in both fully differentiated adipose cells and pre-adipocytes undergoing differentiation. In parallel, beta-catenin levels, a marker of canonical WNT signalling, were reduced. Serum levels of DKK1 were also increased in several of the patients with type 2 diabetes after treatment with rosiglitazone for 90 days. CONCLUSIONS/ INTERPRETATION: These results provide a novel mechanism whereby peroxisome proliferator-activated receptor-gamma activation can terminate WNT signalling and promote adipogenesis. Furthermore, they provide an explanation for why TZD treatment can lead to reduced bone formation and increased risk of fractures, since inhibited WNT signalling in progenitor cells promotes adipogenesis while osteogenesis is reduced.
Authors: Jeffrey M Gimble; Sanjin Zvonic; Z Elizabeth Floyd; Moustapha Kassem; Mark E Nuttall Journal: J Cell Biochem Date: 2006-05-15 Impact factor: 4.429
Authors: Marianna C Politou; Deborah J Heath; Amin Rahemtulla; Richard Szydlo; Athanasios Anagnostopoulos; Meletios A Dimopoulos; Peter I Croucher; Evangelos Terpos Journal: Int J Cancer Date: 2006-10-01 Impact factor: 7.396
Authors: Andrew Grey; Mark Bolland; Greg Gamble; Diana Wattie; Anne Horne; James Davidson; Ian R Reid Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: Danielle Diarra; Marina Stolina; Karin Polzer; Jochen Zwerina; Michael S Ominsky; Denise Dwyer; Adelheid Korb; Josef Smolen; Markus Hoffmann; Clemens Scheinecker; Desiree van der Heide; Robert Landewe; Dave Lacey; William G Richards; Georg Schett Journal: Nat Med Date: 2007-01-21 Impact factor: 53.440
Authors: S Benvenuti; I Cellai; P Luciani; C Deledda; S Baglioni; C Giuliani; R Saccardi; B Mazzanti; S Dal Pozzo; E Mannucci; A Peri; M Serio Journal: J Endocrinol Invest Date: 2007-10 Impact factor: 4.256
Authors: Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti Journal: Diabetes Care Date: 2008-01-25 Impact factor: 19.112
Authors: Ann Hammarstedt; Shahram Hedjazifar; Lachmi Jenndahl; Silvia Gogg; John Grünberg; Birgit Gustafson; Eva Klimcakova; Vladimir Stich; Dominique Langin; Markku Laakso; Ulf Smith Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205
Authors: Chaekyu Kim; Ok Hee Jeon; Do Hun Kim; J Jeremy Chae; Lucas Shores; Nicholas Bernstein; Rahul Bhattacharya; Jeannine M Coburn; Kevin J Yarema; Jennifer H Elisseeff Journal: Biomaterials Date: 2015-12-31 Impact factor: 12.479
Authors: Jian Ruan; Timothy N Trotter; Li Nan; Rongcheng Luo; Amjad Javed; Ralph D Sanderson; Larry J Suva; Yang Yang Journal: Bone Date: 2013-07-27 Impact factor: 4.398